Immunovant, Inc.: directors' dealings · United States · SEC (Form 4)

About Immunovant, Inc.

Immunovant, Inc. (ticker: IMVT) is a U.S.-based clinical-stage immunology company listed on Nasdaq in the United States. For French-speaking investors, it is best understood as a high-risk, high-upside biotech story rather than a mature pharmaceutical business. The company is focused on autoimmune disease, with a development strategy built around novel monoclonal antibodies that target FcRn, a mechanism designed to reduce pathogenic IgG autoantibodies that drive a range of immune-mediated disorders. Immunovant describes itself as a patient-focused clinical-stage company aiming to enable normal lives for people living with autoimmune diseases. The company’s roots go back to 2018, when the original operating entity was founded. In December 2019, it completed a transaction with Health Sciences Acquisitions Corporation, after which the combined company adopted the Immunovant, Inc. name and began trading as IMVT on Nasdaq. Immunovant is headquartered in New York, New York, United States, with additional operations in North Carolina. That footprint reflects a classic U.S. biotech structure: corporate leadership and capital markets access in New York, with scientific and operational activity supported elsewhere in the country. Immunovant’s core pipeline is centered on two investigational assets: IMVT-1402 and batoclimab. Both are fully human monoclonal antibodies intended to be administered subcutaneously, with the potential to be tailored by disease stage and severity. The company’s competitive positioning depends on demonstrating deeper and more durable IgG suppression, as well as a clinically meaningful benefit/risk profile versus other FcRn-directed therapies. This is a crowded and strategically important area of immunology, where differentiation will likely come from data quality, dosing flexibility, safety, and the ability to expand across multiple indications. The main therapeutic areas in development include myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves’ disease, thyroid eye disease (TED), Sjögren’s disease, and cutaneous lupus erythematosus. Immunovant has also highlighted broader potential across autoimmune conditions, reinforcing the platform-like nature of its FcRn strategy. Recent corporate milestones have been significant. In 2025, Immunovant reported positive Phase 3 results for batoclimab in myasthenia gravis and positive early results in CIDP, supporting the underlying FcRn thesis. Throughout 2025 and into 2026, the company has increasingly positioned IMVT-1402 as its next growth driver while continuing to advance potentially registrational studies in endocrine and autoimmune diseases. In April 2026, the company announced Phase 3 results for batoclimab in thyroid eye disease, an important readout for investors tracking clinical execution and the transition of the pipeline. Overall, Immunovant remains a Nasdaq-listed U.S. clinical biotech with a promising platform, but its valuation and outlook remain heavily dependent on trial outcomes, regulatory progress, and financing capacity.